World Health Organization. Global tuberculosis report. Geneva: WHO; 2014. Available at: http://www. who.int/tb/publications/global_report/gtbr14_executive_summary.pdf
PhypersM,HarrisT,PowerC.,,2006,CNS tuberculosis: a longitudinal analysis of epidemiological and clinical features,Int J Tuberc Lung Dis,10,99-103
AbdelmalekR,KanounF,KilaniB,TiouiriH,ZouitenF,GhoubantiniA,,2006,Tuberculous meningitis in adults: MRI contribution to the diagnosis in 29 patients,Int J Infect Dis,10,372-7
Hoang MaiNT,ThwaitesGE,,2016,The current pharmacological landscape of tuberculous meningitis: where to next?,Expert Rev Clin Pharmacol,9,625-7
ThwaitesGE,Van ToornR,SchoemanJ,,2013,Tuberculous meningitis: more questions, still too few answers,Lancet Neurol,12,999-1010
TaiMLS,,2013,Tuberculous meningitis: diagnostic and radiological features, pathogenesis and biomarkers,Neuro sci Med,4,101-7
World Health,,2010,Organization. Guidelines for treatment of tuberculosis (4th ed),WHO;,,147-
,2010,The chemotherapy of tuberculous meningitis in children and adults,Tuberculosis (Edinb),90,375-92
EllardGA,HumphriesMJ,AllenBW,,1993,Cerebrospinal fluid drug concentrations and the treatment of tuberculous meningitis,Am Rev Respir Dis,148,650-5
RuslamiR,GaniemAR,DianS,AprianiL,AchmadTH,van der VenAJ,,2013,Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomized controlled phase 2 trial,Lancet Infect Dis,13,27-35
LolachiS,JanssensJP,AdlerDL,,2017,Tuberculous meningitis,what's new? J Neuro infect Dis,8,2-
LubaschA,KellerI,BornerK,KoeppeP,LodeH,,,Comparative pharmacokinetics of ciprofloxacin,,,,-
ShandilRK,JayaramR,KaurP,GaonkarS,SureshBL,MaheshBN,,2007,Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy,Antimicrob Agents Chemother,51,576-82
BurmanWJ,GoldbergS,JohnsonJL,MuzanyeG,EngleM,MosherAW,,2006,Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis,Am J Respir Crit Care Med,174,331-8
AlmeidaD,NuermbergerE,TyagiS,BishaiWR,GrossetJ.,,2007,In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis,Antimicrob Agents Chemother,51,4261-6
VanTTT,FarrarJ,,2014,-nervous-system-tuberculosis,,68,2-3
WasayM,FarooqS,KhowajaZA,BawaZA,AliSM,,2014,Cerebral infarction and tuberculoma in central nervous system tuberculosis: frequency and prognostic implications,J Neurol Neurosurg Psychiatry,85,1260-4
SheuJJ,YuanRY,YangCC,,2009,Predictors for outcome and treatment delay in patients with tuberculous meningitis,Am J Med Sci,338,134-9
GillespieSH,CrookAM,McHughTD,MendelCM,MeredithSK,MurraySR,,2014,Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis,N Engl J Med,371,1577-87
SpigelmanMK,,2007,New tuberculosis therapeutics: a growing pipeline,J Infect Dis,196,S28-34
TakiffH,GuerreroE.,,2011,Current prospects for the fluoroquinolones as first-line tuberculosis therapy,Antimicrob Agents Chemother,551,5421-9
FouadM,GallagherJC,,2011,Moxifloxacin as an alternative or additive therapy for treatment of pulmonary tuberculosis,Ann Pharmacother,45,1439-44
KanellakopoulouK,PagoulatouA,StroumpoulisK,VafiadouM,KranidiotiH,GiamarellouH,,2008,Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect,J Antimicrob Chemother,61,1328-31
AlffenaarJW,van AltenaR,BokkerinkHJ,LuijckxGJ,van SoolingenD,AanoutseRE,,2009,Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis,Clin Infect Dis,49,1080-2
Ostergaard , C,SorensenTK,KnudsenJD,Frimodt-Moller N,,1998,Evaluation of moxifloxacin, a new 8-methoxyquinolone, for treatment of meningitis caused by a penicillin-resistant pneumococcus in rabbits,Antimicrob Agents Chemother,42,1706-12
Rodriguez-CerratoV,McCoigCC,MichelowIC,GhaffarF,JafriHS,HardyRD,,2001,Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis,Antimicrob Agents Chemother,45,3092-7
CondeMB,EfronA,LoredoC,De SouzaGR,GraçaNP,CezarMC,,2009,Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomized, controlled phase II trial,Lancet,373,1183-9
RodríguezJC,RuizM,ClimentA,RoyoG.,,2001,In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis,Int J Antimicrob Agents,17,229-31
AlffenaarJW,de VriesPM,LuijckxGJ,van SoolingenD,van der WerfTS,van AltenaR.,,2008,Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis,Antimicrob Agents Chemother,52,2293-5
NijlandHM,RuslamiR,SurotoAJ,BurgerDM,AlisjahbanaB,van CrevelR,,2007,Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis,Clin Infect Dis,45,1001-7
WeinerM,BurmanW,LuoCC,PeloquinCA,EngleM,GoldbergS,,2007,Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin,Antimicrob Agents Chemother,51,2861-6
NaidooA,NaidooK,McllleronH,EssackS,PadayatchiN.,,2017,A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis,J Clin Pharmacol,57,1369-86
DonaldPR,,2016,Chemotherapy for Tuberculous Meningitis,N Engl J Med,374,179-81
Te BrakeL,DianS,GaniemAR,RuesenC,BurgerD,DondersR,,2015,Pharmacokinetic/ pharmacodynamic analysis of an intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis,Int J Antimicrob Agents,45,496-503
HeemskerkAD,BangND,MaiNT,,2016,Intensified antituberculosis therapy in adults with tuberculous meningitis,N Engl J Med,374,124-4
ThwaitesGE,BhavnaniSM,ChauTT,HammelJP,TörökME,Van WartSA,,2011,Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis,Antimicrob Agents Chemother,55,3244-53